Key result
Oncology treatments carry persistent MACE risk requiring early risk stratification and multidisciplinary management.
Why the study?
Despite advancements in cancer treatments, the potential for major adverse cardiovascular events persists regardless of prior cardiac history.
A multidisciplinary cardio-oncology approach utilizing early risk stratification and routine surveillance is essential to mitigate the cardiovascular toxicities of modern cancer therapies.
No takes yet. Share an insight, caveat, or question.
Risk stratification with HFA-ICOS remains relevant amid evolving cancer therapies; leaves open prospective validation of monitoring thresholds.
Samuel et al. (2023) conducted a review in Cardiac toxicities in oncology. Oncology treatments was evaluated. Oncology treatments carry a persistent risk of major adverse cardiovascular events, necessitating early risk stratification, baseline imaging, and multidisciplinary management to reduce risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: